Literature DB >> 25266071

Evaluation of the microscopic observation drug susceptibility assay for the rapid detection of MDR-TB and XDR-TB in China: a prospective multicentre study.

Zikun Huang1, Cheng Qin2, Jinghui Du3, Qing Luo1, Yaoxing Wang4, Wang Zhang5, Xi Zhang6, Guoliang Xiong7, Jie Chen1, Xiaomeng Xu1, Weiting Li1, Junming Li8.   

Abstract

OBJECTIVES: To perform a multicentre study evaluating the performance of the microscopic observation drug susceptibility (MODS) assay for the detection of MDR-TB and XDR-TB in high-burden resource-limited settings.
METHODS: We performed a prospective diagnostic accuracy study of drug-resistant TB suspects from outpatient and inpatient settings in five laboratories in China. Sputum was tested by smear microscopy, liquid [mycobacterial growth indicator tube (MGIT)] culture and the MODS assay at each site. Drug susceptibility testing (DST) was by MODS and an indirect 1% proportion method. The reference standard for Mycobacterium tuberculosis detection was growth on MGIT culture; the 1% proportion method was the reference standard for rifampicin, isoniazid, ofloxacin, kanamycin and capreomycin DST.
RESULTS: M. tuberculosis was identified by reference standard culture among 213/532 (40.0%) drug-resistant TB suspects. Overall MODS sensitivity for M. tuberculosis detection was 87.8%-94.3% and specificity was 96.8%-100%. For drug-resistant TB diagnosis, excellent agreement was obtained for all drugs tested at the majority of sites. The accuracy was 87.1%-96.7% for rifampicin, 87.1%-93.3% for isoniazid, 92.7%-100% for ofloxacin, 90.9%-100% for kanamycin and 90.2%-100% for capreomycin. The median time to culture positivity was significantly shorter for MODS than for the MGIT liquid culture (8 days versus 11 days, P<0.001). The contamination rate ranged between 2.1% and 5.3%.
CONCLUSIONS: In the study settings, MODS provided high sensitivity and specificity for rapid diagnosis of TB and drug-resistant TB. We consider it to have a strong potential for timely detection of MDR-TB and XDR-TB in high-burden resource-limited settings.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  diagnosis; drug resistance; second-line drugs; tuberculosis

Mesh:

Substances:

Year:  2014        PMID: 25266071     DOI: 10.1093/jac/dku384

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for Mycobacterium tuberculosis.

Authors:  Donald G Catanzaro; Andre P Trollip; Marva Seifert; Sophia B Georghiou; Richard S Garfein; Timothy C Rodwell; Antonino Catanzaro; Kathleen D Eisenach
Journal:  Eur Respir J       Date:  2017-04-05       Impact factor: 16.671

2.  Performance of microscopic observation drug susceptibility for the rapid diagnosis of tuberculosis and detection of drug resistance in Bamako, Mali.

Authors:  M Sanogo; B Kone; B Diarra; M Maiga; B Baya; A M Somboro; Y S Sarro; A C G Togo; B P P Dembele; D Goita; A Kone; O M'Baye; N Coulibaly; S Diabate; B Traore; M H Diallo; Y I Coulibaly; P Saleeb; M Belson; S Orsega; S Siddiqui; M A Polis; S Dao; R L Murphy; S Diallo
Journal:  Clin Microbiol Infect       Date:  2017-01-18       Impact factor: 8.067

3.  Non-commercial phenotypic assays for the detection of Mycobacterium tuberculosis drug resistance: a systematic review.

Authors:  Irina Kontsevaya; Jim Werngren; Yen Holicka; Kadri Klaos; Anh Tran; Vladyslav Nikolayevskyy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-10-30       Impact factor: 3.267

4.  A Microfluidic Channel Method for Rapid Drug-Susceptibility Testing of Pseudomonas aeruginosa.

Authors:  Yoshimi Matsumoto; Shouichi Sakakihara; Andrey Grushnikov; Kazuma Kikuchi; Hiroyuki Noji; Akihito Yamaguchi; Ryota Iino; Yasushi Yagi; Kunihiko Nishino
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

5.  Multicenter evaluation of crystal violet decolorization assay (CVDA) for rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis.

Authors:  Ahmet Yilmaz Coban; Ahmet Ugur Akbal; Can Bicmen; Ali Albay; Ali Korhan Sig; Meltem Uzun; Deniz Sertel Selale; Nuri Ozkutuk; Suheyla Surucuoglu; Nurhan Albayrak; Nilay Ucarman; Aydan Ozkutuk; Nuran Esen; Ismail Ceyhan; Mustafa Ozyurt; Bayhan Bektore; Gonul Aslan; Nuran Delialioğlu; Alpaslan Alp
Journal:  Sci Rep       Date:  2016-12-16       Impact factor: 4.379

6.  Detecting Mutations in the Mycobacterium tuberculosis Pyrazinamidase Gene pncA to Improve Infection Control and Decrease Drug Resistance Rates in Human Immunodeficiency Virus Coinfection.

Authors:  Matthew Z Dudley; Patricia Sheen; Robert H Gilman; Eduardo Ticona; Jon S Friedland; Daniela E Kirwan; Luz Caviedes; Richard Rodriguez; Lilia Z Cabrera; Jorge Coronel; Louis Grandjean; David A J Moore; Carlton A Evans; Luz Huaroto; Víctor Chávez-Pérez; Mirko Zimic
Journal:  Am J Trop Med Hyg       Date:  2016-10-24       Impact factor: 2.345

7.  Multidrug-resistant strains of Mycobacterium complex species in Egyptian farm animals, veterinarians, and farm and abattoir workers.

Authors:  Hossam A Abdelsadek; Hassan M Sobhy; Kh F Mohamed; Sahar H A Hekal; Amany N Dapgh; Ashraf S Hakim
Journal:  Vet World       Date:  2020-10-14

8.  Bracelet- and self-directed observational therapy for control of tuberculosis: study protocol for a cluster randomized controlled trial.

Authors:  Ruixue Huang; Guofeng Ren; Jianan Hu
Journal:  Trials       Date:  2017-07-04       Impact factor: 2.279

9.  Cough Frequency During Treatment Associated With Baseline Cavitary Volume and Proximity to the Airway in Pulmonary TB.

Authors:  Alvaro Proaño; David P Bui; José W López; Nancy M Vu; Marjory A Bravard; Gwenyth O Lee; Brian H Tracey; Ziyue Xu; Germán Comina; Eduardo Ticona; Daniel J Mollura; Jon S Friedland; David A J Moore; Carlton A Evans; Philip Caligiuri; Robert H Gilman
Journal:  Chest       Date:  2018-03-17       Impact factor: 9.410

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.